Alkixen 250 mg (Crizotinib) 60 Capsule| Price, Uses, & Safety Guide

Alkixen 250 mg (Crizotinib) is a highly potent, orally administered tyrosine kinase inhibitor (TKI). As a targeted antineoplastic agent, it selectively inhibits the anaplastic lymphoma kinase (ALK), ROS1, and hepatocyte growth factor receptor (HGFR, c-Met) receptor tyrosine kinases. It is strictly indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive or ROS1-positive, as detected by an FDA-approved companion diagnostic test. By directly binding to the ATP-binding pocket of these specific kinases, Alkixen halts downstream signaling pathways (such as PI3K/AKT and MEK/ERK) responsible for tumor cell proliferation and survival, offering a targeted alternative to generalized cytotoxic chemotherapy.

Specialist’s Insight about Alkixen 250 mg

“In thoracic oncology, the management of metastatic non-small cell lung cancer has undergone a radical paradigm shift. We have moved entirely away from a one-size-fits-all chemotherapy approach toward precise molecular profiling. The identification of ALK and ROS1 rearrangements presented an opportunity for targeted intervention, but historical access to these first-generation TKIs has been a persistent barrier due to the prohibitive cost of innovator brands. Integrating high-quality, bioequivalent generics like Alkixen is a critical clinical strategy. It allows us to secure immediate, uninterrupted receptor blockade for our patients, ensuring that optimal progression-free survival is dictated entirely by tumor biology and clinical science, rather than being limited by geographic or economic constraints.” -Dr. Salma Elreedy, Clinical Oncologis

Clinical Data: Mechanism, Dosing, and Efficacy

Who is the exact candidate for this medication?

Alkixen 250 mg is indicated strictly by the FDA approval for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have been tested and confirmed to be:

• ALK-Positive Metastatic NSCLC: Confirmed via Fluorescence In Situ Hybridization (FISH) (e.g., Vysis ALK Break Apart FISH Probe Kit) or validated Next-Generation Sequencing (NGS).
• ROS1-Positive Metastatic NSCLC: Confirmed via targeted NGS or FISH diagnostics.

How does Crizotinib work at a molecular level?

Crizotinib is a selective small-molecule inhibitor. It suppresses ALK and ROS1 kinase activity, subsequently downregulating the MEK/ERK, PI3K/AKT, and JAK/STAT survival pathways.

Excretion: Fecal excretion accounts for 63% of the administered dose, while renal clearance accounts for 22%. The mean terminal half-life is exactly 42 hours.

Absorption: Median time to peak concentration (Tmax) is 4 to 6 hours. Administration with a high-fat meal decreases AUC by approximately 14%; however, it is clinically approved to be taken with or without food.

Distribution: Highly bound to human plasma proteins (91%), independent of drug concentration.

Metabolism: Primarily hepatic, predominantly mediated by the CYP3A4/5 enzymes.

What are the standard dosage and administration protocols?

The standard clinical dose for Alkixen is 250 mg taken orally twice daily (every 12 hours).

• Administration: The capsules must be swallowed whole with water. Do not crush, dissolve, or open the capsules. It can be administered with or without food.
• Missed Doses: If a dose is missed, take it as soon as remembered, unless the next scheduled dose is due within 6 hours. In that case, skip the missed dose. Never take two doses at the same time.
• Dietary Restrictions: Patients must strictly avoid consuming grapefruit or grapefruit juice, as these inhibit the CYP3A enzyme system and can lead to dangerous levels of the drug in the bloodstream.

What is the expected safety profile and how are adverse events managed?

What is the clinical trial evidence supporting its use?

The clinical superiority of crizotinib in ALK+ NSCLC was definitively established in landmark trials:

• PROFILE 1014 (1L ALK+ NSCLC): Demonstrated a statistically significant improvement in Progression-Free Survival (PFS) with a median of 10.9 months compared to 7.0 months for standard pemetrexed-platinum chemotherapy (Hazard Ratio [HR] = 0.45; p < 0.0001). Objective Response Rate (ORR) was 74% vs. 45%.
• Real-World Evidence (RWE): Post-marketing data indicates that while resistance mutations (e.g., L1196M) inevitably develop, initial systemic disease control achieved by crizotinib provides a crucial foundation, allowing subsequent sequencing to second or third-generation ALK inhibitors (like alectinib or lorlatinib) effectively.

Precautions & Special Populations

• Pregnancy: Based on its mechanism of action and animal data, crizotinib causes embryo-fetal toxicity. Females of reproductive potential must use highly effective contraception during treatment and for at least 45 days following the final dose. Males with female partners of reproductive potential must use condoms during treatment and for 90 days after.
• Lactation: Breastfeeding is strictly contraindicated during treatment and for 45 days after the final dose due to potential serious adverse reactions in the breastfed child.
• Pediatric Use: Safety and efficacy in patients younger than 18 years have not been established.
• Renal Impairment: For patients with severe renal impairment (Creatinine Clearance < 30 mL/min) not requiring dialysis, the Alkixen dose must be reduced to 250 mg once daily. No adjustment is needed for mild to moderate impairment.
• Hepatic Impairment: Crizotinib is extensively metabolized in the liver. Dose reductions are required for moderate to severe pre-existing hepatic impairment.
• Storage Logistics: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C. Standard room-temperature logistics apply; cold-chain transport is not required.

Drug-Drug Interaction Matrix

Manufacturer Quality Assurance, Ordering Guide Under Named Patient Program, Brand vs Generic Comparison

Manufacturer Quality Assurance

Alkixen is manufactured by Everest Pharmaceutical, a highly regarded oncology manufacturer operating specialized, state-of-the-art facilities. Production adheres strictly to World Health Organization Good Manufacturing Practices (WHO-GMP) and ISO 9001 certifications. To ensure an exact match with the innovator brand’s safety and efficacy profile, Everest enforces rigorous bioequivalence testing, ensuring precise dissolution kinetics, API purity, and systemic absorption rates.

Ordering Guide & Personal Importation (NPP)

For patients in jurisdictions where Alkixen is not yet commercially registered, targeted access is achieved through the Named Patient Program (NPP) or specific Personal Importation protocols. This regulated framework permits the legal procurement of life-saving medications.

1.Customs & Ministry of Health (MOH) Clearance: Specialized medical exporters handle all requisite regulatory documentation to ensure safe, legal, and uninterrupted transit directly to the patient or treating hospital.

2.Medical Verification: Submit a valid, physically signed prescription from a licensed, treating oncologist.

3.Clinical Justification: Provide a formal Letter of Medical Necessity detailing the confirmed biomarker status (ALK+ or ROS1+) and the clinical requirement for Crizotinib over locally available alternatives.

Comparison Table

Frequently Asked Questions (FAQs)